BioPorto A/S (CPH:BIOPOR) (FRA:2P4) announced that its chief executive officer of nearly eight years, Peter Mørch Eriksen, will resign his position with the company once his successor has been found.
Mørch Eriksen, however, will continue to support the company until the end of January 2022.
“I wish to thank Peter for his tremendous efforts for the company over many years. I and the rest of the organization look forward to continue working with Peter over the coming months, as we proceed to identify and appoint his successor and further advance the ongoing transition of the company to the North American market,” BioPorto A/S Chairman Thomas Magnussen said in a statement.
READ: BioPorto focused on flagship NGAL acute kidney-injury test but also looking at coronavirus test
Mørch Eriksen also commented, stating: “It is, and has been, a privilege to be CEO of BioPorto, and I look forward to continue to support the company’s ongoing projects, including the clinical studies and expected submission this summer of a De Novo application to the FDA for pediatric use of The NGAL Test.”
“Considering the important milestones ahead for BioPorto, I find this to be the right time to find my successor who can lead the company into its next phase.”
BioPorto A/S is an in-vitro diagnostic company based in Hellerup, Denmark, that provides health-care professionals in 80 countries a range of diagnostic tests and antibodies to treat obesity and diabetes, innate immunity, allergies and infectious diseases.
The Copenhagen-listed company, founded in 2000, has been aggressively marketing its proprietary NGAL Test, which provides an early risk assessment of acute kidney injury (AKI), a well-known complication that is common after surgeries such as kidney transplants and heart-bypass.
Contact Sean at [email protected]